Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $16.90 Consensus Target Price from Analysts

Roivant Sciences Ltd. (NASDAQ:ROIV) has been given an average rating of “Moderate Buy” by the ten research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $16.90.

Several research analysts have commented on ROIV shares. Wolfe Research started coverage on Roivant Sciences in a report on Thursday, February 15th. They set an “outperform” rating and a $17.00 price objective on the stock. Truist Financial restated a “buy” rating and set a $23.00 price objective on shares of Roivant Sciences in a report on Monday, March 25th. Bank of America raised their price objective on Roivant Sciences from $11.00 to $12.00 and gave the stock a “neutral” rating in a report on Tuesday, January 2nd. Deutsche Bank Aktiengesellschaft raised their price objective on Roivant Sciences from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Finally, HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Monday, April 22nd.

Insiders Place Their Bets

In other Roivant Sciences news, COO Eric Venker sold 96,950 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $10.92, for a total transaction of $1,058,694.00. Following the completion of the sale, the chief operating officer now directly owns 532,207 shares in the company, valued at approximately $5,811,700.44. The transaction was disclosed in a document filed with the SEC, which is available through this link. 4.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Retirement Systems of Alabama acquired a new position in Roivant Sciences in the first quarter valued at approximately $4,464,000. Privium Fund Management B.V. lifted its stake in Roivant Sciences by 104.4% during the first quarter. Privium Fund Management B.V. now owns 567,795 shares of the company’s stock worth $5,985,000 after purchasing an additional 290,000 shares in the last quarter. Principal Financial Group Inc. lifted its stake in Roivant Sciences by 3,413.9% during the first quarter. Principal Financial Group Inc. now owns 1,274,737 shares of the company’s stock worth $13,436,000 after purchasing an additional 1,238,460 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Roivant Sciences by 66.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 154,910 shares of the company’s stock worth $1,633,000 after purchasing an additional 61,921 shares in the last quarter. Finally, Securian Asset Management Inc. acquired a new position in Roivant Sciences during the first quarter worth $293,000. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Roivant Sciences Trading Down 2.1 %

Roivant Sciences stock opened at $10.90 on Friday. The business has a 50-day simple moving average of $10.90 and a two-hundred day simple moving average of $10.38. The company has a market cap of $8.78 billion, a P/E ratio of 2.10 and a beta of 1.34. Roivant Sciences has a 52-week low of $8.06 and a 52-week high of $13.24. The company has a quick ratio of 27.79, a current ratio of 27.79 and a debt-to-equity ratio of 0.06.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Tuesday, February 13th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.07. The company had revenue of $37.14 million for the quarter, compared to analysts’ expectations of $30.72 million. Roivant Sciences had a negative return on equity of 33.38% and a net margin of 3,624.14%. Analysts predict that Roivant Sciences will post -1.36 EPS for the current year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.